Recent patents on endocrine, metabolic & immune drug discovery最新文献_第3页

Psychopathological Behaviour and Cognition in Morbid Obesity. 病态肥胖的心理病理行为和认知。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2017-01-01 DOI: 10.2174/1872214810666161226162823

A. Calderone, Pasquale Fabio Calabrò, Chita Lippi, R. Jaccheri, J. Vitti, F. Santini

{"title":"Psychopathological Behaviour and Cognition in Morbid Obesity.","authors":"A. Calderone, Pasquale Fabio Calabrò, Chita Lippi, R. Jaccheri, J. Vitti, F. Santini","doi":"10.2174/1872214810666161226162823","DOIUrl":"https://doi.org/10.2174/1872214810666161226162823","url":null,"abstract":"BACKGROUND Obesity is a chronic condition with high prevalence and multifaceted aetiology, accompanied by an increased risk of morbidity and mortality. Obesity has several negative effects on the psychological status, and the severity of psychological disorders correlates with the degree of obesity. OBJECTIVE Aim of this review is to provide an overview of the literature concerning the psychological distress associated with severe obesity, which contributes to deterioration of the quality of life of affected patients. METHODS Dysfunctional eating behaviours and eating disorders, psychiatric comorbidity, cognition and quality of life will be discussed together with the most common drugs that can be employed to treat the various disorders in this peculiar clinical setting. The effects of bariatric surgery will be also reviewed. RESULTS Obesity is often the result of pathological behaviours implemented in an eating disorder. Inconsistent results have been reported with regard to the effect of severe obesity on cognition, which recognize a multifaceted aetiology. Serotonergic agents play an important role in the management of patients with obesity and binge episodes, fluoxetine being currently a drug approved for this disorder. The efficacy of lorcaserin, a combination of bupropion and naltrexone, or antiepileptic medications (topiramate and zonisamide) has also been proposed. A neuroprotective role of leptin and oestrogen has been hypothesized. Bariatric surgery is a helpful treatment of morbid obese patients, with long-term favourable results on the psychopathological profile. CONCLUSION Psychological, psychoeducational and psychopharmacological treatment can facilitate weight loss in morbid obese subjects with psychopathological comorbidities. A precise definition of the mechanisms affecting appetite, satiety and energy balance is expected to foster the development of new effective antiobesity drugs.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"39 1","pages":"112-118"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85955292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly). 社论(专题问题:老年人内分泌失调和认知功能)。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-03-31 DOI: 10.2174/187221481001161005181628

G. Pasqualetti, V. Calsolaro, F. Monzani

引用次数: 0

Inflammasome as a New Therapeutic Target for Diabetic Complications. 炎性小体作为治疗糖尿病并发症的新靶点。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-03-31 DOI: 10.2174/1872214810666160219163314

C. Volpe, Paula M F Anjos, J. A. Nogueira-Machado

{"title":"Inflammasome as a New Therapeutic Target for Diabetic Complications.","authors":"C. Volpe, Paula M F Anjos, J. A. Nogueira-Machado","doi":"10.2174/1872214810666160219163314","DOIUrl":"https://doi.org/10.2174/1872214810666160219163314","url":null,"abstract":"BACKGROUND\u0000Inflammation is an innate immune response which is considered a common basis for several diseases such as ageing, diabetes, obesity, gout, neurodegenerative diseases and others. Among other platforms, inflammasomes are part of a superfamily of Pattern Recognition Receptors (PRR) and act as cytoplasmatic sensors for stimulation with Pathogen Associated Molecular Pattern (PAMPs) and/or Danger/Damage-Associated Molecular Patterns (DAMPs) leading to an infectious/ pathogenic or sterile inflammation. Inflammasomes constitute a complex platform with high molecular weight and functionality, divided into two families: NOD-like or NLR and PYHIN (pyrin and HIN200 - hematopoietic interferoninducible nuclear antigens). After activation by PAMPs or DAMPs, NLRP3 inflammasome promotes conversion of procaspase 1 in caspase-1 to form the active complex which is able to cleave pro-IL-1β and pro-IL-18 in respective active inflammatory cytokines IL-1β and IL-18 inducing cellular death by pyroptosis. Diabetes has a very intricate pathology with metabolic adaptation and inflammatory components apparently responsible for diabetic complications.\u0000\u0000\u0000OBJECTIVE\u0000The present review evaluates the role of inflammasome, emphasizing NRLP3 on diabetes. An overview on several inflammatory diseases in which inflammasomes appear to play a role is included. Patents on inflammasomes associated with diabetes are evaluated and discussed.\u0000\u0000\u0000CONCLUSION\u0000There are a significant number of patents on inflammation but few of them are specifically on inflammasome and diabetes. The patents WO2015003246; US20130273588; WO2012016145; and CN104258398 are shown and their mechanisms are discussed. In conclusion, deeply studies on inflammasomes mechanisms will help the proposition of new therapeutic targets for controlling inflammatory process in diabetic complications.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"18 1","pages":"56-62"},"PeriodicalIF":0.0,"publicationDate":"2016-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80834807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence. 老年男性血清睾酮与认知功能:最新证据。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-03-31 DOI: 10.2174/1872214810999160603213743

V. Giagulli, E. Guastamacchia, B. Licchelli, V. Triggiani

{"title":"Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence.","authors":"V. Giagulli, E. Guastamacchia, B. Licchelli, V. Triggiani","doi":"10.2174/1872214810999160603213743","DOIUrl":"https://doi.org/10.2174/1872214810999160603213743","url":null,"abstract":"BACKGROUND\u0000Testosterone (T) deficit, either in prepubertal or postpubertal form of hypogonadism, seems to play a key role in impairing cognitive function, including memory, attention, language and visuospatial abilities, especially in elderly men.\u0000\u0000\u0000OBJECTIVE\u0000Several studies have recently showed the association between low serum T levels and important cognitive dysfunctions in ageing male as well as in subjects suffering from Alzheimer's disease (AD), mild cognitive impairment (MCI) and even depression, suggesting that T could exert an active neuroprotective role.\u0000\u0000\u0000METHODS\u0000By searching PubMed and recent patents (ranging from 2010 to 2015), we identified several observational and intervention studies dealing with T and cognitive function in adult and ageing men. Findings were reviewed, thoroughly examined and, finally, summarized herein.\u0000\u0000\u0000RESULTS\u0000Although a large number of studies have been carried out so far, conclusive evidence cannot be drawn, in particular, for cognitive disorders in males. Conversely, T supplementation has been suggested for depressive syndrome in young and ageing men. To date, no clinical data have been carried out on cognitive dysfunctions employing the quoted patents in men.\u0000\u0000\u0000CONCLUSIONS\u0000Studies aiming to evaluate the role of serum T and its supplementation in adult and ageing men with T deficiency syndrome need to be encouraged, given that subjects affected by overt hypogonadism, either in prepubertal (i.e. Klinefelter syndrome) or postpubertal forms (chemical castration in subjects affected by prostate cancer), often complain of cognitive dysfunction, and seem to considerably benefit from T replacement therapy.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"167 1","pages":"22-30"},"PeriodicalIF":0.0,"publicationDate":"2016-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76609902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure. 认知功能与衰老过程:轻度甲状腺功能衰竭的特殊作用。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810666160701110509

Giuseppe Pasqualetti, Nadia Caraccio, Umberto Dell Agnello, Fabio Monzani

{"title":"Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure.","authors":"Giuseppe Pasqualetti, Nadia Caraccio, Umberto Dell Agnello, Fabio Monzani","doi":"10.2174/1872214810666160701110509","DOIUrl":"https://doi.org/10.2174/1872214810666160701110509","url":null,"abstract":"Background: Over the last decades an increasing body of evidence suggested a possible relationship between thyroid hormone (TH) and the ageing process, and several efforts have been made to determine the actual role of TH dynamic during human life. It is still unclear whether the serum level shift of Thyroid Stimulating Hormone toward higher value, observed during ageing, is a normal adaptive response associated with senescence or an actual mild thyroid dysfunction. A growing body of evidence supports the hypothesis of a reset of the hypothalamus-pituitary-thyroid axis in order to contrast the catabolic status of the ageing process. On the other hand, several meta-analyses showed a direct link between subclinical hypothyroidism (sHT) and cardiovascular events (both ischemic heart disease and stroke), although mainly in individuals younger than 65 years. Similarly, a recent meta-analysis documented consistent data on a positive relationship between sHT and cognitive impairment, but only in individuals younger than 75 years.Conclusion: The available data suggest a complex relationship between mild thyroid failure and the ageing process as well as the development and progression of several cardiovascular and neurological diseases. In this paper, we reviewed the scientific English literature on sHT and the ageing process focusing on experimental evidences related to cognitive impairment and dementia. Moreover, we focused on new patents of treatments potentially able to improve the care of sHT patients, especially in the elderly, where treatment drawbacks may have negative impact on the long term outcome.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"4-10"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666160701110509","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34654037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Cognitive Function and Heart Failure: The Role of the Adrenergic System. 认知功能和心力衰竭:肾上腺素能系统的作用。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810666160513150244

Grazia D Femminella, Ciro Candido, Maddalena Conte, Sandra Provenzano, Carlo Rengo, Enrico Coscioni, Nicola Ferrara

{"title":"Cognitive Function and Heart Failure: The Role of the Adrenergic System.","authors":"Grazia D Femminella, Ciro Candido, Maddalena Conte, Sandra Provenzano, Carlo Rengo, Enrico Coscioni, Nicola Ferrara","doi":"10.2174/1872214810666160513150244","DOIUrl":"https://doi.org/10.2174/1872214810666160513150244","url":null,"abstract":"Background: Heart Failure (HF) and cognitive impairment (CI) represent two high incident diseases worldwide, with extremely elevated mortality and morbidity rates. Their prevalence is expected to further increase in the next years due to the aging population, thus they pose enormous clinical, social and economic challenges. Sympathetic nervous system hyperactivity is known to play a pivotal role in HF pathophysiology and progression. In fact, increased cardiac and circulating catecholamine levels are responsible for several molecular and structural abnormalities with detrimental effects on the failing heart. The proof of this latter concept is represented by the clinical success of .-Blocker therapy that is able to attenuate HF-related morbidity and mortality. Recently, adrenergic system alterations have been implied also in the pathogenesis of CI and dementia opening the window for new fascinating and promising therapeutic opportunities.Objective: Assess the state of the art on the relationship between cognitive impairment and heart failure.Method: In the present manuscript, we propose an updated review of literature and patent on the role of sympathetic nervous system derangement in the pathogenesis of HF and CI.Conclusion: We have discussed recent findings allowing the identification of new molecular targets that hopefully will contribute to the generation of effective therapeutic strategies for HF and dementia. In this article, the patents US20100048479, US7060871, WO2006052857, US7351401, US5721243, WO1994009155, US5449604, WO1999058981, US5985581, EP2319511, EP2377534, EP2650303, WO2006004939, WO2010132128 and EP1779858 are summarized.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"40-49"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666160513150244","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34479206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Cushing's Syndrome and Steroid Dementia. 库欣综合征和类固醇性痴呆。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810666160809113021

Giampaolo Bernini, Domenico Tricò

{"title":"Cushing's Syndrome and Steroid Dementia.","authors":"Giampaolo Bernini, Domenico Tricò","doi":"10.2174/1872214810666160809113021","DOIUrl":"https://doi.org/10.2174/1872214810666160809113021","url":null,"abstract":"Cushing's Syndrome (CS) is associated with a specific spectrum of dementia-like symptoms, including psychiatric disorders, such as major depression, anxiety and mania, and neurocognitive alterations, like impairment of memory and concentration. This pattern of clinical complications, which significantly impair the health-related quality of life of CS patients, is sometimes referred to as \"steroid dementia syndrome\" (SDS). The SDS is the result of anatomical and functional anomalies in brain areas involved in the processing of emotion and cognition, which are only partially restored after the biochemical remission of the disease. Therefore, periodical neuropsychiatric evaluations are recommended in all CS patients, and a long-term follow-up is required after normalization of hypercortisolism. Recent evidences demonstrate that three classes of drugs (glucocorticoid receptor antagonists, steroidogenesis inhibitors, and pituitary tumor-targeted drugs), which are used for medical treatment of CS, can rapidly relief neuropsychiatric symptoms of SDS. Furthermore, several psychoactive medications have demonstrated effectiveness in the treatment of symptoms induced by the acute or chronic glucocosteroid administration. In this paper, a review of the current and future patents for the treatment and prevention of CS and SDS will be presented.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"50-55"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666160809113021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34748562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis. 抑制银屑病患者肿瘤坏死因子α活性的新方法。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810666160426151906

Borys A Gerasun

{"title":"New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis.","authors":"Borys A Gerasun","doi":"10.2174/1872214810666160426151906","DOIUrl":"https://doi.org/10.2174/1872214810666160426151906","url":null,"abstract":"Introduction: A new method of reduction of tumor necrosis factor alpha activity via intradermal immunization with inactivated autoleukocytes (patent UA97493 (2015) [1]) has been presented in the article. New patents from various countries have been analyzed [2-7].Objective: Patients with psoriasis (24) with high level of tumor necrosis factor alpha in their blood (. 30pg/ml) were immunized with autoleukocytes.Method: Leukocytes were isolated by centrifuging plasma, obtained after precipitation of a patient's heparinized peripheral venous blood. Precipitate was suspended in 1.0 - 1.5ml of a patient's blood serum and 0.1ml of blood was injected into the skin of the back. For determination of autoleukocyte immunization efficacy, concentration of tumor necrosis factor alpha in a patient's blood was compared prior to immunization and at different periods after immunization.Results: In 30 days after single immunization, a considerable decrease in cytokine concentration was observed in all patients (100%); it reduced to zero in 16 out of 24 of immunized individuals (66.7%). The degree of reduction and duration of the achieved effect were individual, thus, if necessary the immunization was repeated several times. The procedure was well tolerated, and general condition of patients was improved.Conclusion: The method of reduction of tumor necrosis factor alpha activity is recommended for implementation into clinical practice.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"63-66"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666160426151906","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34343862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Parkinson's Disease, Diabetes and Cognitive Impairment. 帕金森病、糖尿病和认知障碍。

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810999160628105549

Mohammad R Ashraghi, Gennaro Pagano, Sotirios Polychronis, Flavia Niccolini, Marios Politis

{"title":"Parkinson's Disease, Diabetes and Cognitive Impairment.","authors":"Mohammad R Ashraghi, Gennaro Pagano, Sotirios Polychronis, Flavia Niccolini, Marios Politis","doi":"10.2174/1872214810999160628105549","DOIUrl":"10.2174/1872214810999160628105549","url":null,"abstract":"Background: Parkinson's disease is a chronic neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons. The pathophysiological mechanisms underlying Parkinson's are still unknown. Mitochondrial dysfunction, abnormal protein aggregation, increased neuroinflammation and impairment of brain glucose metabolism are shared processes among insulinresistance, diabetes and neurodegeneration and have been suggested as key mechanisms in development of Parkinson's and cognitive impairment.Objective: To review experimental and clinical evidence of underlying Parkinson's pathophysiology in common with diabetes and cognitive impairment. Anti-diabetic agents and recent patents for insulin-resistance that might be repositioned in the treatment of Parkinson's also have been included in this review.Method: A narrative review using MEDLINE database.Results: Common antidiabetic treatments such as DPP4 inhibitors, GLP-1 agonists and metformin have shown promise in the treatment of Parkinson's disease and cognitive impairment in animals and humans. Study of the pathophysiology of neurodegeneration common between diabetes and Parkinson's disease has given rise to new treatment possibilities. Patents published in the last 5 years could be used in novel approaches to Parkinson's treatment by targeting specific pathophysiology proteins, such as Nurr1, PINK1 and NrF2, while patents to improve penetration of the blood brain barrier could allow improved efficacy of existing treatments.Conclusion: Further studies using GLP-1 agonists and DPP-4 inhibitors to treat PD are warranted as they have shown promise.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"11-21"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34652610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alterations in Glucose Metabolism in Alzheimer's Disease. 阿尔茨海默病中葡萄糖代谢的改变

Recent patents on endocrine, metabolic & immune drug discovery Pub Date : 2016-01-01 DOI: 10.2174/1872214810666160615102809

Valeria Calsolaro, Paul Edison

{"title":"Alterations in Glucose Metabolism in Alzheimer's Disease.","authors":"Valeria Calsolaro, Paul Edison","doi":"10.2174/1872214810666160615102809","DOIUrl":"https://doi.org/10.2174/1872214810666160615102809","url":null,"abstract":"Background: Alzheimer's disease (AD) is the most frequent type of dementia in people over 65 years of age; type 2 diabetes mellitus is a metabolic condition affecting 382 million of adults worldwide. Glucose is the main substrate for energy for the brain, which consumes 25% of the body's glucose. Glucose metabolism, evaluated using Positron Emission Tomography (PET) scanning using 18F-fluorodeoxyglucose ([18F]-FDG) is commonly used for diagnosis and follow up in AD. Epidemiological and pathophysiological studies showed a link between AD and diabetes, particularly in relation to insulin resistance.Objective: In this paper, we discuss how [18F] FDG is a marker of glucose metabolism, how insulin resistance is related to diabetes, the link between diabetes and AD, and how novel treatments for diabetes could be beneficial in the treatment of Alzheimer's disease. We also review few recent patents in the field, suggesting both diagnostic and therapeutic potential approaches.Methods: The electronic searches were performed in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases. We also manually searched abstract books and reviewed available recent patents on specific websites.Results: The impaired glucose metabolism in the brain of subject with AD is a widely recognised early feature of the disease; in vivo evaluation with PET is a useful diagnostic tool. The link between diabetes and neurodegeneration is widely recognized and offer a target for novel therapeutic strategies.Conclusions: Early diagnosis and early therapeutic intervention are needed to approach this devastating disease. Important studies targeting different aspect of the disease are currently ongoing.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"10 1","pages":"31-39"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214810666160615102809","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34483064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 51